Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Top Cited Papers
- 13 November 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 22 (1) , 42-61
Abstract
Rheumatoid arthritis is an autoimmune disease that affects ~1% of the global population and leads to joint inflammation, local bone erosions and systemic bone loss. The disability and immobility caused by inflammatory bone loss, joint destruction and fractures in rheumatoid arthritis present a clinical challenge and impose a considerable socioeconomical burden. Osteoclasts have the unique ability to resorb bone and cause bone loss. A comprehensive understanding of the regulatory mechanisms of osteoclasts and their crosstalk with stromal cells, such as osteoblasts, or immune cells during inflammation is essential for the development of targeted therapies to prevent and treat bone loss. The objective of this Review is to present a comprehensive overview of the current knowledge of osteoclast regulation at different levels: from systemic pathways to changes in the bone microenvironment, including the involvement of local cells, to osteoclast-intrinsic regulation such as metabolic adaptations. We also discuss some of the current and emerging therapies that can counteract inflammatory bone loss.Keywords
This publication has 292 references indexed in Scilit:
- Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid ArthritisACR Open Rheumatology, 2023
- Initiation of Tumor Necrosis Factor α Antagonists and Risk of Fractures in Patients With Selected Rheumatic and Autoimmune DiseasesArthritis Care & Research, 2012
- American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosisArthritis Care & Research, 2010
- Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritisArthritis Care & Research, 2010
- Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patientsArthritis Care & Research, 2010
- Tumor necrosis factor α‐mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerinArthritis & Rheumatism, 2002
- Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritisArthritis & Rheumatism, 2001
- The effect of methotrexate on mouse bone cells in cultureArthritis & Rheumatism, 1996
- Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three‐year randomized, double‐blind trialArthritis & Rheumatism, 1996
- The Effect of Low‐Dose Methotrexate on Bone Metabolism and Histomorphometry in RatsArthritis & Rheumatism, 1994